ClinicalTrials.gg
CompletedNCT02408289Updated Jan 13, 2016

The Randomized Controlled Cocoa-Appetite Trial

An interventional study of Lo-Flav and Hi-Flav in Obesity, sponsored by Brooklyn College of the City University of New York. Completed at 1 site in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-13.

Sponsored by Brooklyn College of the City University of New York · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

The purpose of this study is to determine whether high-flavonoid cocoa can decrease appetite in humans. In addition the study is designed to test epicatechin, a compound found in cocoa and procyanidins, a class of compounds found in cocoa, for their ability to decrease appetite in humans.

Read the detailed description

The study is a four-way randomized double-blinded crossover trial with randomization balanced for beverage and lab visit order.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 28 is below the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Brooklyn College of the City University of New York is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stable-weight, as indicated by weight gain or loss of \<2% in the past 6 months;
  • engaging in only mild exercise\< twice a week;
  • moderate alcohol users, \<2 drinks/day;
  • willing to eat pizza.
  • mentally and physically healthy.

Exclusion criteria

Exclusion Criteria:

  • smokers regular;
  • frequent drinkers of coffee, tea or cola sodas, >daily;
  • underweight or obese (: \<18.5 or >30 Kg/m2);
  • allergies to chocolate, cocoa, green tea, coffee or pizza;
  • using medication;
  • interested in registering in the future for the course Health \& Nutrition Sciences 2140, Introduction to the U.S. Health Care System, that is often taught by the PI of the proposed study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Placebo comparator
    Lo-Flav

    Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage

    Dietary Supplement: Lo-Flav

  • Active comparator
    Hi-Flav

    Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.

    Dietary Supplement: Hi-Flav

  • Active comparator
    Epicatechin

    Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.

    Dietary Supplement: Epicatechin

  • Active comparator
    Procyanidins

    Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.

    Dietary Supplement: Procyanidins

Interventions

  • Dietary supplementLo-Flav

    low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.

  • Dietary supplementHi-Flav

    High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.

  • Dietary supplementCatechinStudies of CatechinCatechin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage

  • Dietary supplementProcyanidins

    Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.

06

What researchers measure

Primary outcomes

  1. Appetite as assessed by amount of pizza eaten.

    Amount of pizza eaten to be assessed two and one half hours after ingestion of the beverage.

    Time frame: Two and a half hours

Secondary outcomes

  1. Appetite as assessed by a Visual Analog Scale

    Visual Analog Scale assessments to be conducted during the two and one half hours after ingestion of the beverage.

    Time frame: Two and one half hours

07

Study locations

1 site
  • Brooklyn College of the City University of New York
    Brooklyn, New York 11210, United States
08

References and documents

Publications

  • Greenberg JA, O'Donnell R, Shurpin M, Kordunova D. Epicatechin, procyanidins, cocoa, and appetite: a randomized controlled trial. Am J Clin Nutr. 2016 Sep;104(3):613-9. doi: 10.3945/ajcn.115.129783. Epub 2016 Aug 10. PubMed 27510533 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2015
First posted
Apr 3, 2015
Start
Mar 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Last update
Jan 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02408289
Lead sponsor
Brooklyn College of the City University of New York
Responsible party
James Greenberg (Associate Professor, Department of Health & Nutrition Sciences,, Brooklyn College of the City University of New York) — Principal investigator
First posted
Apr 3, 2015
Start date
Mar 2015
Primary completion
May 2015
Completion
May 2015
Last update
Jan 13, 2016

Study contacts

James Greenberg, Ph.D
principal investigator · Department of Health & Nutritional Sciences, Brooklyn College of the City University of New York

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catechin

Start the discussion